STEPS TAKEN AFTER GRANTING THE MARKETING AUTHORIZATION  
For procedures finalised after 01/04/2004 please refer to module 8B. 
Scope 
Application 
number 
Type of 
modification1 
Notification/ 
Opinion 
issued on2 
Commission 
Decision 
Issued/amen
ded on 
19/12/2002  09/01/2003 
18/12/2002  09/01/2003 
19/12/2002  09/01/2003 
20/02/2003  06/03/2003 
25/09/2003  02/10/2003 
22/10/2003  30/10/2003 
22/10/2003  30/10/2003 
II/0001 
II/0002 
II/0003 
II/0004 
II/0005 
II/0006 
II/0007 
II 
II 
II 
II 
II 
II 
II 
II/0010 
II 
21/01/04 
31/03/04 
Change(s) to the test method(s) and/or specifications 
for the active substance 
Change(s) to the manufacturing process for the active 
substance 
Change(s) to shelf-life or storage conditions 
Change(s) to the manufacturing process for the active 
substance 
Change(s) to the test method(s) and/or specifications 
for the finished product 
Change(s) to the manufacturing process for the active 
substance 
Change(s) to the manufacturing process for the active 
substance 
Amendment  of  sections  4.1,  4.2,  4.5,  4.8,  5.1  of  the 
Summary  of  Product  Characteristics  (SPC)  to  extend 
the  indication  to  include  also  children  aged  1  to  5 
years.  As  a  consequence  of  the  age  extension,  the 
MAH  applied 
the 
include 
concomitant  administration  of  Ambirix  with  DTPa-
IPV/Hib  or  MMR  vaccines  at  separate  injection  sites 
in  the  second  year  of  life.The  Package  Leaflet  (PL) 
and  labelling  have  been  amended  accordingly.  In 
addition,  the  contacts  of  the  German,  Spanish,  Irish, 
Portuguese and Finnish local representatives have been 
amended. 
information  on 
to 
Change in or addition of manufacturing site(s) for part 
or all of the manufacturing process 
Change of the vaccine manufacturing facilities (filling 
and packaging) from "GlaxoSmithkline Biologicals 
Manufacturing SA" (GSK Bio Manufacturing) to 
"GlaxoSmithkline Biologicals SA" (GSK Bio). 
I/0009 
IA/0011 
I 
IA 
18/07/2003 
12/03/2004 
- 
- 
1 In accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended: I refers to a 
minor variation (Type I variation); II refers to a major variation (Type II variation); I/II refers to a minor 
variation following the procedure set out in Article 6, 7 and 8 of the Regulation; X refers to an Annex II 
application. 
T refers to a transfer of a Marketing Authorisation in accordance with Commission Regulation (EC) No 2141/96 
of 7 November 1996.  
N refers to a notification in accordance with Article 10(3) of Council Directive 92/27/EEC of 31 March 1992. 
2 For Notifications and Type I variations, the date of entry into force of the change is the EMEA Notification 
date. The Commission Decision will be amended accordingly. 
1/1 
ï£©EMEA 2005 
 
 
 
 
 
 
  
 
 
                                                            
 
 
